Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2026 · 10-Q
Revenue$4.22K$4.22K−93.8% vs Q1 2025 Net Income-$2.14M-$2.14MN/M vs Q1 2025 EPS Diluted-$0.47-$0.47N/M vs Q1 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$930,492N/M Margins · derivedGross margin43.8%+6.5 pt vs Q1 2025
Operating margin-23176.4%−20759.2 pt vs Q1 2025
Net margin-50579.3%−45258.4 pt vs Q1 2025
ended Mar 31, 2026 · filed May 20, 2026 · 50 d after period end